泛素蛋白酶体系统在免疫调节和治疗中的应用

IF 4 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Sameer Ahmed Bhat, Zahra Vasi, Ritika Adhikari, Anish Gudur, Asceal Ali, Liping Jiang, Rachel Ferguson, David Liang, Shafi Kuchay
{"title":"泛素蛋白酶体系统在免疫调节和治疗中的应用","authors":"Sameer Ahmed Bhat,&nbsp;Zahra Vasi,&nbsp;Ritika Adhikari,&nbsp;Anish Gudur,&nbsp;Asceal Ali,&nbsp;Liping Jiang,&nbsp;Rachel Ferguson,&nbsp;David Liang,&nbsp;Shafi Kuchay","doi":"10.1016/j.coph.2022.102310","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span>The ubiquitin proteasome system (UPS) is a proteolytic machinery for the degradation of protein substrates that are post-translationally conjugated with </span>ubiquitin polymers through the enzymatic action of </span>ubiquitin ligases<span>, in a process termed ubiquitylation<span>. Ubiquitylation of substrates precedes their proteolysis </span></span></span><em>via</em><span> proteasomes, a hierarchical feature of UPS. E3-ubiquitin ligases recruit protein substrates providing specificity for ubiquitylation. Innate and adaptive immune system networks are regulated by ubiquitylation and substrate degradation </span><em>via</em> E3-ligases/UPS. Deregulation of E3-ligases/UPS components in immune cells is involved in the development of lymphomas, neurodevelopmental abnormalities, and cancers. Targeting E3-ligases for therapeutic intervention provides opportunities to mitigate the unintended broad effects of 26S proteasome inhibition. Recently, bifunctional moieties such as PROTACs and molecular glues have been developed to re-purpose E3-ligases for targeted degradation of unwanted aberrant proteins, with a potential for clinical use. Here, we summarize the involvement of E3-ligases/UPS components in immune-related diseases with perspectives.</p></div>","PeriodicalId":50603,"journal":{"name":"Current Opinion in Pharmacology","volume":null,"pages":null},"PeriodicalIF":4.0000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"7","resultStr":"{\"title\":\"Ubiquitin proteasome system in immune regulation and therapeutics\",\"authors\":\"Sameer Ahmed Bhat,&nbsp;Zahra Vasi,&nbsp;Ritika Adhikari,&nbsp;Anish Gudur,&nbsp;Asceal Ali,&nbsp;Liping Jiang,&nbsp;Rachel Ferguson,&nbsp;David Liang,&nbsp;Shafi Kuchay\",\"doi\":\"10.1016/j.coph.2022.102310\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span><span><span>The ubiquitin proteasome system (UPS) is a proteolytic machinery for the degradation of protein substrates that are post-translationally conjugated with </span>ubiquitin polymers through the enzymatic action of </span>ubiquitin ligases<span>, in a process termed ubiquitylation<span>. Ubiquitylation of substrates precedes their proteolysis </span></span></span><em>via</em><span> proteasomes, a hierarchical feature of UPS. E3-ubiquitin ligases recruit protein substrates providing specificity for ubiquitylation. Innate and adaptive immune system networks are regulated by ubiquitylation and substrate degradation </span><em>via</em> E3-ligases/UPS. Deregulation of E3-ligases/UPS components in immune cells is involved in the development of lymphomas, neurodevelopmental abnormalities, and cancers. Targeting E3-ligases for therapeutic intervention provides opportunities to mitigate the unintended broad effects of 26S proteasome inhibition. Recently, bifunctional moieties such as PROTACs and molecular glues have been developed to re-purpose E3-ligases for targeted degradation of unwanted aberrant proteins, with a potential for clinical use. Here, we summarize the involvement of E3-ligases/UPS components in immune-related diseases with perspectives.</p></div>\",\"PeriodicalId\":50603,\"journal\":{\"name\":\"Current Opinion in Pharmacology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2022-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Opinion in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1471489222001370\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1471489222001370","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 7

摘要

泛素蛋白酶体系统(UPS)是一种蛋白质水解机制,通过泛素连接酶的酶促作用,降解翻译后与泛素聚合物结合的蛋白质底物,这一过程被称为泛素化。底物的泛素化先于蛋白酶体的蛋白水解,这是UPS的一个分层特征。e3 -泛素连接酶募集蛋白质底物,为泛素化提供特异性。先天和适应性免疫系统网络通过e3 -连接酶/UPS受泛素化和底物降解调节。免疫细胞中e3连接酶/UPS成分的失调与淋巴瘤、神经发育异常和癌症的发生有关。靶向e3连接酶进行治疗干预为减轻26S蛋白酶体抑制的意外广泛影响提供了机会。最近,双功能部分(如PROTACs和分子胶)被开发出来,重新利用e3连接酶靶向降解不需要的异常蛋白,具有临床应用的潜力。在这里,我们从不同角度总结了e3连接酶/UPS组分在免疫相关疾病中的作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Ubiquitin proteasome system in immune regulation and therapeutics

The ubiquitin proteasome system (UPS) is a proteolytic machinery for the degradation of protein substrates that are post-translationally conjugated with ubiquitin polymers through the enzymatic action of ubiquitin ligases, in a process termed ubiquitylation. Ubiquitylation of substrates precedes their proteolysis via proteasomes, a hierarchical feature of UPS. E3-ubiquitin ligases recruit protein substrates providing specificity for ubiquitylation. Innate and adaptive immune system networks are regulated by ubiquitylation and substrate degradation via E3-ligases/UPS. Deregulation of E3-ligases/UPS components in immune cells is involved in the development of lymphomas, neurodevelopmental abnormalities, and cancers. Targeting E3-ligases for therapeutic intervention provides opportunities to mitigate the unintended broad effects of 26S proteasome inhibition. Recently, bifunctional moieties such as PROTACs and molecular glues have been developed to re-purpose E3-ligases for targeted degradation of unwanted aberrant proteins, with a potential for clinical use. Here, we summarize the involvement of E3-ligases/UPS components in immune-related diseases with perspectives.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.80
自引率
2.50%
发文量
131
审稿时长
4-8 weeks
期刊介绍: Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信